The revenue zoomed 15.84% to Rs. 2367.66 millions for the quarter ended December 2019 as compared to Rs. 2043.93 millions during the corresponding quarter last year.Net Profit for the quarter ended December 2019 zoomed to 183.38% from Rs. 134.84 millions to Rs. 382.11  millions.Operating profit for the quarter ended December 2019 rose to 550.80 millions as compared to 225.20 millions of corresponding quarter ended December 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201912 201812 % Var Sales 2367.66 2043.93 15.84 9265.98 8489.95 9.14 9265.98 8489.95 9.14 Other Income 60.57 71.75 -15.58 479.44 243.88 96.59 479.44 243.88 96.59 PBIDT 550.80 225.20 144.58 2515.24 1725.35 45.78 2515.24 1725.35 45.78 Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PBDT 550.80 225.20 144.58 2515.24 1791.00 40.44 2515.24 1791.00 40.44 Depreciation 42.84 46.30 -7.47 171.65 211.20 -18.73 171.65 211.20 -18.73 PBT 507.96 178.90 183.94 2343.59 1579.80 48.35 2343.59 1579.80 48.35 TAX 125.85 44.06 185.63 756.01 562.43 34.42 756.01 562.43 34.42 Deferred Tax -12.90 19.44 -166.36 39.26 60.15 -34.73 39.26 60.15 -34.73 PAT 382.11 134.84 183.38 1587.58 1017.37 56.05 1587.58 1017.37 56.05 Equity 165.99 165.99 0.00 165.99 165.99 0.00 165.99 165.99 0.00 PBIDTM(%) 23.26 11.02 111.14 27.14 20.32 33.57 27.14 20.32 33.57

Procter & Gamble Health is currently trading at Rs. 4278.60, up by 7.10 points or 0.17% from its previous closing of Rs. 4271.50 on the BSE.The scrip opened at Rs. 4282.20 and has touched a high and low of Rs. 4282.20 and Rs. 4266.00 respectively. So far 121 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 5120.80 on 29-Jul-2019 and a 52 week low of Rs. 2866.25 on 26-Feb-2019.Last one week high and low of the scrip stood at Rs. 4394.00 and Rs. 4190.00 respectively. The current market cap of the company is Rs. 7102.21 crore.The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 14.28% and 33.91% respectively.Procter & Gamble Health (P&G Health) has entered into partnership with the Public Health Foundation of India (PHFI) to implement a digital health project in the state of Goa under its corporate social responsibility (CSR) program ‘SEHAT’.P&G Health (formerly Merck) operates both its pharmaceuticals and chemicals businesses in the country. Merck was also the first Merck Group Company to go public in the year 1981.

P&G Health is currently trading at Rs. 4262.00, up by 6.00 points or 0.14% from its previous closing of Rs. 4256.00 on the BSE.The scrip opened at Rs. 4270.35 and has touched a high and low of Rs. 4293.00 and Rs. 4252.45 respectively. So far 219 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 5120.80 on 29-Jul-2019 and a 52 week low of Rs. 2786.50 on 11-Dec-2018.Last one week high and low of the scrip stood at Rs. 4395.00 and Rs. 4236.35 respectively. The current market cap of the company is Rs. 7058.80 crore.The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 14.06% and 34.13% respectively.Procter & Gamble Health (P&G Health) has launched ‘Panache’- a first of its kind platform to support India’s Gen X doctors in their medical education journey. Panache aims to assist students in honing crucial skills for holistic patient care viz. medico-legal aspects, ethics, role of technology, emotional intelligence, decision making, good communication, teamwork, problem solving and leadership among others.P&G Health (formerly Merck) operates both its pharmaceuticals and chemicals businesses in the country. Merck was also the first Merck Group Company to go public in the year 1981.

The December 2018 quarter revenue stood at Rs. 2043.93 millions, up 14.47% as compared to Rs. 1785.56 millions during the corresponding quarter last year.Net profit declined -1.87% to Rs. 134.84 millions from Rs. 137.41 millions.Operating Profit saw a handsome growth to 225.20 millions from 116.38 millions in the quarter ended December 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201812 201712 % Var Sales 2043.93 1785.56 14.47 8489.95 7114.68 19.33 8489.95 7114.68 19.33 Other Income 71.75 75.19 -4.58 243.88 240.70 1.32 243.88 240.70 1.32 PBIDT 225.20 116.38 93.50 1725.35 1010.38 70.76 1725.35 1010.38 70.76 Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PBDT 225.20 286.37 -21.36 1791.00 1180.37 51.73 1791.00 1180.37 51.73 Depreciation 46.30 51.06 -9.32 211.20 191.20 10.46 211.20 191.20 10.46 PBT 178.90 235.31 -23.97 1579.80 989.17 59.71 1579.80 989.17 59.71 TAX 44.06 97.90 -54.99 562.43 378.80 48.48 562.43 378.80 48.48 Deferred Tax 19.44 -68.73 -128.28 60.15 -66.60 -190.32 60.15 -66.60 -190.32 PAT 134.84 137.41 -1.87 1017.37 610.37 66.68 1017.37 610.37 66.68 Equity 165.99 165.99 0.00 165.99 165.99 0.00 165.99 165.99 0.00 PBIDTM(%) 11.02 6.52 69.04 20.32 14.20 43.10 20.32 14.20 43.10

A decent increase of about 26.88% in the sales to Rs. 2202.88 millions was observed for the quarter ended June 2018. The sales figure stood at Rs. 1736.16 millions during the year-ago period.The Total revenue for the quarter ended June 2018 of  Rs. 328.20  millions  grew by 171.71% from Rs. 120.79 millions.OP of the company witnessed a marginal growth to 566.07 millions from 199.16 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201712 201612 % Var Sales 2202.88 1736.16 26.88 5214.56 4105.38 27.02 11194.51 10297.74 8.71 Other Income 57.69 48.43 19.12 112.56 115.58 -2.61 239.69 244.07 -1.79 PBIDT 566.07 199.16 184.23 1037.45 492.11 110.82 1616.05 1399.84 15.45 Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.00 PBDT 566.07 199.16 184.23 1102.80 492.11 124.10 1785.95 1399.84 27.58 Depreciation 48.94 47.37 3.31 134.50 109.71 22.60 264.03 248.11 6.42 PBT 517.13 151.79 240.69 968.30 382.40 153.22 1521.92 1151.73 32.14 TAX 188.93 31.00 509.45 412.96 113.34 264.36 582.83 360.46 61.69 Deferred Tax 24.64 -24.30 -201.40 45.59 -48.16 -194.66 -102.42 -99.44 3.00 PAT 328.20 120.79 171.71 555.34 269.06 106.40 939.09 791.27 18.68 Equity 165.99 165.99 0.00 165.99 165.99 0.00 165.99 165.99 0.00 PBIDTM(%) 25.70 11.47 124.01 19.90 11.99 65.97 14.44 13.59 6.20

Merck is currently trading at Rs. 1777.10, up by 267.10 points or 17.69% from its previous closing of Rs. 1510.00 on the BSE.The scrip opened at Rs. 1548.00 and has touched a high and low of Rs. 1812.00 and Rs. 1539.50 respectively. So far 92522 shares were traded on the counter.The BSE group `B` stock of face value Rs. 10 has touched a 52 week high of Rs. 1812.00 on 19-Apr-2018 and a 52 week low of Rs. 977.00 on 03-Jul-2017.Last one week high and low of the scrip stood at Rs. 1812.00 and Rs. 1507.10 respectively. The current market cap of the company is Rs. 2944.73 crore.The promoters holding in the company stood at 51.80%, while Institutions and Non-Institutions held 13.25% and 34.95% respectively.Merck has signed an agreement to sell its global consumer health business to Procter & Gamble (P&G) for around euro 3.4 billion in cash, or around $4.2 billion at current exchange rates. The transaction, which is expected to close by the end of the fourth quarter 2018, is subject to regulatory approvals and satisfaction of certain other customary closing conditions.Merck intends to use the net proceeds from the divestiture primarily to accelerate deleveraging. At the same time, it will allow Merck to increase flexibility to strengthen all three business sectors.Merck is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments. The company operates through two segments - Pharmaceuticals and Chemicals.

The Revenue for the quarter ended  December 2017 of Rs. 3041.30 millions grew by 17.20 % from Rs. 2595.01 millions.A good growth in profit of 40.25% reported to Rs. 272.70  millions over Rs. 194.44 millions of corresponding previous quarter.Operating Profit saw a handsome growth to 361.19 millions from 319.46 millions in the quarter ended December 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201612 201512 % Var Sales 3041.30 2595.01 17.20 11194.52 10297.75 8.71 9963.35 9395.00 6.05 Other Income 53.97 81.65 -33.90 239.29 243.70 -1.81 242.40 232.98 4.04 PBIDT 361.19 319.46 13.06 1616.05 1399.96 15.44 1377.74 1067.45 29.07 Interest 0.00 0.00 0.00 0.09 0.11 -18.18 0.00 0.00 0.00 PBDT 531.18 319.46 66.27 1785.96 1399.85 27.58 1377.74 1067.45 29.07 Depreciation 70.65 61.25 15.35 264.03 248.12 6.41 275.50 234.16 17.65 PBT 460.53 258.21 78.35 1521.93 1151.73 32.14 1102.24 833.29 32.28 TAX 187.83 63.77 194.54 582.83 360.46 61.69 343.30 297.66 15.33 Deferred Tax -105.41 -40.13 162.67 -78.56 -50.56 55.38 0.00 0.00 0.00 PAT 272.70 194.44 40.25 939.10 791.27 18.68 758.94 535.63 41.69 Equity 165.99 165.99 0.00 165.99 165.99 0.00 165.99 165.99 0.00 PBIDTM(%) 11.88 12.31 -3.53 14.44 13.59 6.19 13.83 11.36 21.71

Merck is currently trading at Rs. 1574.15, down by 66.70 points or 4.06 % from its previous closing of Rs. 1640.85 on the BSE.The scrip opened at Rs. 1634.00 and has touched a high and low of Rs. 1634.00 and Rs. 1563.00 respectively. So far 8189 shares were traded on the counter.The BSE group `B` stock of face value Rs. 10 has touched a 52 week high of Rs. 1687.30 on 15-Jan-2018 and a 52 week low of Rs. 933.00 on 23-Jan-2017.Last one week high and low of the scrip stood at Rs. 1687.30 and Rs. 1310.00 respectively. The current market cap of the company is Rs. 2631.00 crore.The promoters holding in the company stood at 51.80%, while institutions and non-institutions held 14.46% and 33.74% respectively.The country’s largest insurer, Life Insurance Corporation of India (LIC) has sold 2.06% stake in drug and chemical firm Merck through an open market transaction. With the sale, the total shareholding of the insurer has come down to 5.6%. The insurer has sold 3,43,147 shares totaling 2.06% in the company. Earlier, LIC had 12,74,823 shares in the company constituting 7.68% stake. Merck is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments. The company operates through two segments - Pharmaceuticals and Chemicals.

Merck has informed that a section of the work force at the Company`s Goa plant have stopped work, while the Company and the workers union are engaged in negotiating the workers charter of demand, which includes wage revision. The Company Management is striving to convince the union to resume work and to resume negotiations. The Company has already activated its business continuity plans to maintain stable supply to the market, and therefore does not foresee material impact on sales or availability of products due to the stoppage of work by such workmen.The above information is a part of company’s filings submitted to BSE.

Merck has informed that a meeting of the Board of Directors of the Company will be held on February 24, 2017, to consider and approve the audited financial results for the year ended December 31, 2016 and to consider recommendation of dividend for the year 2016.The above information is a part of company’s filings submitted to BSE.

With reference to the earlier letter dated October 04, 2016 about the nomination of Zoe Tang, (also known as Mei Lin Tang) by Merck KGaA, Merck has now informed that Zoe Tang has been appointed as the Non- Executive Director of the Company effective December 23, 2016.The above information is a part of company’s filings submitted to BSE.

Merck has informed that the Company has already issued notification to its employees on December 12, 2016 regarding closure of trading window for them for the purposes of consideration and approval of the audited financial results from December 16, 2016 until 48 hours from the publication of the audited financial results for the quarter/year to be ended on December 31, 2016. The Company would be subsequently informing the date of the Board Meeting for the consideration and approval of the above mentioned audited financial results.The above information is a part of company’s filings submitted to BSE.